恩格列净在射血分数保留的心力衰竭中改善结局且不受血压影响:EMPEROR-Preserved 试验
EMPEROR-Preserved 试验随机纳入 5988 例射血分数保留的心力衰竭患者,按基线收缩压分组,评估恩格列净的疗效与安全性。中位随访 26.2 个月,基线收缩压并未显著调节恩格列净对心力衰竭事件的影响,且低血压等不良事件与收缩压无关。
要点
- 恩格列净在射血分数保留的心力衰竭患者中有效且安全。
- 基线收缩压不显著影响恩格列净对心力衰竭事件的疗效。
- 低血压、容量不足和急性肾衰竭等不良事件与收缩压无显著关联。
核心结论
- 在 EMPEROR-Preserved 试验中,恩格列净有效且安全,基线收缩压未显著调节其治疗效果。
研究设计与样本
- EMPEROR-Preserved 试验的随机患者共 5988 例,按基线收缩压分为 110 mmHg 组 455 例、110–130 mmHg 组 2415 例、130 mmHg 组 3118 例。
主要发现
- 中位随访 26.2 个月,安慰剂校正的 eGFR 下降幅度较小,且在不同基线收缩压间无显著差异。
- 安慰剂组心血管死亡或心力衰竭住院风险在 130 mmHg 组为 8.58 事件/100 患者年,110–130 mmHg 组为 8.26,110 mmHg 组为 11.59(P 0.12 vs. 130 mmHg,P 0.08 vs. 110–130 mmHg)。
- 基线收缩压未显著调节恩格列净对心力衰竭事件风险的影响(主要终点交互 P 0.69,复发性心力衰竭住院交互 P 0.55)。
- 与安慰剂相比,恩格列净组低血压、容量不足和急性肾衰竭等不良事件与收缩压无显著关联。
临床怎么用
- 恩格列净可安全有效地用于射血分数保留的心力衰竭患者,无需因基线收缩压水平而调整治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and preserved ejection fraction. This study aims to evaluate if systolic blood pressure (SBP) moderates these effects. METHODS AND RESULTS: The association of SBP and the treatment effects of empagliflozin in EMPEROR-Preserved (empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction) was evaluated. Randomized patients (n 5988) were grouped according to SBP at baseline (110 mmHg, n 455; 110130 mmHg, n 2415; 130 mmHg, n 3118). The effect of empagliflozin on blood pressure, cardiovascular death or HF hospitalization (primary outcome), total HF hospitalizations, and rate of decline in estimated glomerular filtration rate was studied. Over a median of 26.2 months, the placebo-corrected decline was small and not significantly different across baseline SBP. On placebo, the risk of cardiovascular death or hospitalization for HF was 8.58 at 130 mmHg, 8.26 at 110130 mmHg, and 11.59 events per 100 patient-years at 110 mmHg (P 0.12 vs. 130 mmHg, P 0.08 vs. 110130 mmHg). There was no evidence for baseline SBP moderating the effect of empagliflozin on risk of HF events (primary endpoint interaction P 0.69, recurrent HF hospitalizations interaction P 0.55). When comparing empagliflozin with placebo, SBP did not meaningfully associate with adverse events such as hypotension, volume depletion, and acute renal failure. CONCLUSION: In EMPEROR-Preserved, empagliflozin was effective and safe without SBP meaningfully moderating empagliflozins treatment effects. This analysis of EMPEROR-Preserved shows that empagliflozin can be used safely and effectively without blood pressure being a meaningful moderator of the drug benefit. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov Unique identifier: NCT03057951.
引用
- Bhm, Anker, Mahfoud, et al. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J. 2023. PMID: 36478225. doi:10.1093/eurheartj/ehac693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。